A next-generation epinephrine delivery device — 67% smaller, 66% lighter — engineered for the real-world carry compliance that legacy injectors have failed to deliver for decades.
The EpiPen's core design hasn't been meaningfully updated in nearly four decades. Patients carry bulky, inconvenient devices — or worse, leave them behind when they're needed most. With Mylan's key patents expiring, the market is wide open.
The last meaningful EpiPen redesign was in 1987. No other critical medical device has gone this long without innovation.
Mylan's patent protections are expiring — opening a multi-billion-dollar market to entrants with superior technology.
Devices are too large for pockets, clutches, and small bags — patients leave them behind during critical moments.
Even generic EpiPens cost ~$700 per 2-pack, creating massive pricing headroom for innovative alternatives.
Our proprietary ultra-compact auto-injector delivers the same life-saving medication in a form factor patients will actually carry every day. Functional prototypes are complete and ready for commercial tooling.
Interested in the opportunity? Our team can share the full executive summary, pro forma, and regulatory timeline.
A de-risked medical device opportunity targeting a massive, established market with structural deficiencies. We're raising $20M in equity — no debt — to fund FDA clearance, commercial tooling, and go-to-market execution.
Structured recapitalization following regulatory clearance and early commercial validation. Additional pathways include strategic acquisition by Pfizer/Mylan, TEVA, Medtronic, Abbott, BD, or Novo Nordisk.
Epinephrine is just the beachhead. Our drug-agnostic platform serves biologics, migraine therapies, diabetes rescue medications, and emergency overdose interventions — expanding the addressable market by multiples.
Ready to discuss? Schedule a call with our team to review the investment thesis and ask questions.
As a Class II medical device — not a drug — we pursue FDA clearance via the 510(k) pathway, dramatically reducing time, cost, and risk compared to traditional pharmaceutical approvals.
Drug approvals typically require 8–12 years and $500M+. Our device pathway targets clearance in 6–36 months at a fraction of the cost. Drug liability remains entirely with the drug manufacturer.
Regulatory roadmap, commercial-grade prototype, provisional patent filed
Drug portioning partner secured, testing initiated
Tooling finalization, FDA pre-submission meeting, human factors studies
FDA 510(k) submission and clearance, manufacturing begins
Acquisition process with strategic pharma and institutional partners
We'll send you the complete investor package: executive summary, 120-month pro forma, regulatory roadmap, and team bios.